within Pharmacolibrary.Drugs.A_AlimentaryTractAndMetabolism.A10B_BloodGlucoseLoweringDrugsExclInsulins.A10BH03_Saxagliptin;

model Saxagliptin
  extends Pharmacolibrary.Drugs.ATC.A.A10BH03;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>A10BH03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Saxagliptin is an oral antidiabetic medication used for the treatment of type 2 diabetes mellitus. It is a selective inhibitor of the dipeptidyl peptidase-4 (DPP-4) enzyme, which increases incretin levels (GLP-1 and GIP), inhibiting glucagon release and increasing insulin secretion. Saxagliptin is approved and widely used today as a second-line therapy for glycemic control.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult human subjects, both male and female, following a single oral 5 mg dose under fasting conditions.</p><h4>References</h4><ol><li><p>Patel, CG, et al., &amp; Boulton, DW (2011). Saxagliptin, a potent, selective inhibitor of DPP-4, does not alter the pharmacokinetics of three oral antidiabetic drugs (metformin, glyburide or pioglitazone) in healthy subjects. <i>Diabetes, obesity &amp; metabolism</i> 13(7) 604–614. DOI:<a href=\"https://doi.org/10.1111/j.1463-1326.2011.01381.x\">10.1111/j.1463-1326.2011.01381.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21332626/\">https://pubmed.ncbi.nlm.nih.gov/21332626</a></p></li><li><p>Upreti, VV, et al., &amp; Boulton, DW (2012). Effect of saxagliptin on the pharmacokinetics of the active components of Ortho-Cyclen(®), a combined oral contraceptive containing ethinyl estradiol and norgestimate, in healthy women. <i>Diabetes, obesity &amp; metabolism</i> 14(12) 1155–1157. DOI:<a href=\"https://doi.org/10.1111/j.1463-1326.2012.01635.x\">10.1111/j.1463-1326.2012.01635.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22776778/\">https://pubmed.ncbi.nlm.nih.gov/22776778</a></p></li><li><p>Boulton, DW, et al., &amp; Patel, CG (2011). Influence of renal or hepatic impairment on the pharmacokinetics of saxagliptin. <i>Clinical pharmacokinetics</i> 50(4) 253–265. DOI:<a href=\"https://doi.org/10.2165/11584350-000000000-00000\">10.2165/11584350-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/21348538/\">https://pubmed.ncbi.nlm.nih.gov/21348538</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Saxagliptin;
